News for Verve Therapeutics, Inc. (VERV)

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

The consensus price target hints at a 367.9% upside potential for Verve Therapeutics (VERV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Verve Therapeutics (VERV) has granted equity awards to four new employees as part of its 2024 Inducement Stock Incentive Plan. The awards include stock opti

Verve Therapeutics (VERV) exceeds EPS expectations by $0.32 with a significant revenue surge. Strong cash position supports operations through mid-2027,

Verve Therapeutics (VERV) announced impressive first-quarter revenue of $32.976 million, far surpassing the anticipated $9.38 million. The company has made sign

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 50.70% and 362.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

**media[625359]**

Verve Therapeutics (VERV) reports Q1 GAAP EPS of -$0.35, beating estimates; revenue surges 478.6% Y/Y.

**media[613215]**

Take Verve Therapeutics (NASDAQ: VERV), a small-cap, clinical-stage biotech. If Verve Therapeutics has any chance of soaring by more than 300% in the next year, the company will have to impress the market with its leading candidate, VERVE-102. Notably, Verve Therapeutics recently announced positive results from a Phase 1b clinical trial for VERVE-102 as a potential treatment for heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease.

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

Several companies in the biotech sector are witnessing a notable increase in search activity, as observed by InvestingChannel. Among them, Third Harmonic Bio (T

Explore VERV's promising gene-editing therapies, including VERVE-102 with a 69% LDL-C reduction. Click here to read my most recent analysis of VERV stock.

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy.

Editor's Note: This headline has been corrected to reflect that the stock moves occurred on Tuesday U.S. stocks were higher, with the Dow Jones index gaining a...

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of Netflix, Inc. NFLX rose sharply during Tuesday's session after...

Maine-based Synergy CHC Corp. (SNYR) is up over 139 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Verve Therapeutics (VERV) saw a significant rise in stock price after releasing encouraging early-stage clinical data. The Phase Ib study of VERVE-102 s

Verve Therapeutics (VERV) has received a positive update from H.C. Wainwright, which raised its price target for the company's stock to $25 from the previous $1